Spotlight
Clinical
Events
CME
Partners
Subscribe
- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
Alcon licenses anti-infective compound
Fort Worth, TX-Alcon Laboratories' affiliate Alcon Manufacturing Ltd. has signed a collaboration and licensing agreement with NovaCal Pharmaceuticals to research, develop, and commercialize NovaCal's novel Aganocide topical compounds to treat bacterial, viral, and fungal infections in the eye, ear, and sinus.
Fort Worth, TX-Alcon Laboratories' affiliate Alcon Manufacturing Ltd. has signed a collaboration and licensing agreement with NovaCal Pharmaceuticals to research, develop, and commercialize NovaCal's novel Aganocide topical compounds to treat bacterial, viral, and fungal infections in the eye, ear, and sinus.
Related Videos
Related Content
